L
Lulu Wang
Researcher at University of Texas MD Anderson Cancer Center
Publications - 15
Citations - 1003
Lulu Wang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 6, co-authored 12 publications receiving 481 citations.
Papers
More filters
Journal ArticleDOI
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen,Zhenlin Ju,Wei Zhao,Lulu Wang,Yang Peng,Zhongqi Ge,Zachary D. Nagel,Jun Zou,Chen Wang,Prabodh Kapoor,Xiangyi Ma,Ding Ma,Jiyong Liang,Shumei Song,Jinsong Liu,Leona D. Samson,Jaffer A. Ajani,Guo Min Li,Han Liang,Xuetong Shen,Gordon B. Mills,Guang Peng +21 more
TL;DR: Results suggest ARID1A deficiency contributes to impaired MMR and mutator phenotype in cancer, and may cooperate with immune checkpoint blockade therapy, complementing MSI-based prognosis.
Journal ArticleDOI
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen,Wei Zhao,Zhenlin Ju,Lulu Wang,Yang Peng,Marilyne Labrie,Timothy A. Yap,Gordon B. Mills,Guang Peng +8 more
TL;DR: It is shown that PARPi-mediated modulation of the immune response contributes to their therapeutic effects independently of BRCA1/2 mutations, providing a mechanistic rationale for using PARPi as immunomodulatory agents to harness the therapeutic efficacy of immune checkpoint blockade.
Posted ContentDOI
PARPi triggers STING-dependent immune response and enhances therapeutic efficacy of immune checkpoint blockade independent of BRCAness
Jianfeng Shen,Wei Zhao,Zhenlin Ju,Lulu Wang,Yang Peng,Marilyne Labrie,Timothy A. Yap,Gordon B. Mills,Guang Peng +8 more
TL;DR: ParPis modulate immune reposes, which contribute to their therapeutic effects independent of BRCA1/2 mutations, and may provide a mechanistic rationale for using PARPis as immunomodulatory agents to harness therapeutic efficacy of immune checkpoint blockade.
Journal ArticleDOI
Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy
Jiyong Liang,Lulu Wang,Chao Wang,Chao Wang,Jianfeng Shen,Bojin Su,Anantha Marisetty,Dexing Fang,Cynthia Kassab,Kang Jin Jeong,Wei Zhao,Yiling Lu,Abhinav K. Jain,Zhicheng Zhou,Han Liang,Shao Cong Sun,Changming Lu,Zhi-Xiang Xu,Qinghua Yu,Shan Shao,Xiaohua Chen,Meng Gao,Francois X. Claret,Zhiyong Ding,Jian Chen,Pingsheng Chen,Michelle Craig Barton,Guang Peng,Gordon B. Mills,Amy B. Heimberger +29 more
TL;DR: In this article, the authors used reverse-phase protein arrays to assess drugs in use or likely to enter trials, and identified verteporfin as a possible small-molecule inhibitor.
Journal ArticleDOI
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors
Lulu Wang,Lin Yang,Chen Wang,Wei Zhao,Zhenlin Ju,Wei Zhang,Jianfeng Shen,Yang Peng,Clemens An,Yen T. Luu,Shumei Song,Timothy A. Yap,Jaffer A. Ajani,Gordon B. Mills,Xuetong Shen,Guang Peng +15 more
TL;DR: Results suggest that ARID1A's targeting of the nonchromatin substrate Chk2 for ubiquitination makes it possible to selectively modulate cancer cell-intrinsic innate immunity to enhance the antitumor activity of immune checkpoint blockade.